CELYAD ONCOLOGY (CYAD.BR) Stock Income Statement
Europe - EBR:CYAD - BE0974260896 - Common Stock
0.202 EUR
+0 (+0.5%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 186.00K | 186.00K | 102.00K | 0.00 | 0.00 | |||
| Cost Of Goods | 11.00K | 12.00K | 69.00K | 0.00 | 0.00 | |||
| Gross Profit | 175.00K | 174.00K | 33.00K | 0.00 | 0.00 | |||
| Operating Expenses | 6.62M | 6.04M | 9.58M | 5.77M | 26.39M | |||
| Research and Development | 3.44M | 2.89M | 3.88M | 17.70M | 19.50M | |||
| Selling, General, and Administrative Expenses | 3.14M | 3.10M | 5.96M | 10.34M | 9.66M | |||
| Operating Income | -6.44M | -5.87M | -9.54M | -5.77M | -26.39M | |||
| Interest Income/Expense | -25.00K | 72.00K | -41.00K | 2.00K | -206.00K | |||
| Other Income/Expense | N/A | -38.00K | -13.00K | -15.00K | 95.00K | |||
| Non Recurring Items | N/A | 12.00K | 1.09M | -35.08M | -1.00K | |||
| Income Before Taxes | -6.46M | -5.82M | -8.51M | -40.87M | -26.50M | |||
| Income Tax | 0.00 | 0.00 | -63.00K | 65.00K | 10.00K | |||
| Net Income | -6.46M | -5.82M | -8.45M | -40.94M | -26.51M | |||
| EBITDA | -6.02M | -5.42M | -8.75M | -4.33M | -24.87M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.16 | -0.14 | -0.33 | -1.81 | -1.70 | |||
| Statistics | ||||||||
| Gross Profit Margin | 94.09% | 93.55% | 32.35% | N/A | N/A | |||
| Profit Margin | -3470.43% | -3131.18% | -8282.35% | N/A | N/A | |||
| Operating Profit Margin | -3462.90% | -3155.91% | -9356.86% | N/A | N/A | |||
All data in EUR